HRP20201140T1 - Oralna farmaceutska kompozicija - Google Patents
Oralna farmaceutska kompozicija Download PDFInfo
- Publication number
- HRP20201140T1 HRP20201140T1 HRP20201140TT HRP20201140T HRP20201140T1 HR P20201140 T1 HRP20201140 T1 HR P20201140T1 HR P20201140T T HRP20201140T T HR P20201140TT HR P20201140 T HRP20201140 T HR P20201140T HR P20201140 T1 HRP20201140 T1 HR P20201140T1
- Authority
- HR
- Croatia
- Prior art keywords
- uncoated tablet
- tablet according
- trifluorothymidine
- salt
- iminopyrrolidin
- Prior art date
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 title claims 2
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims 5
- 150000002016 disaccharides Chemical class 0.000 claims 4
- 229910052751 metal Inorganic materials 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 150000005846 sugar alcohols Chemical class 0.000 claims 4
- KGHYQYACJRXCAT-UHFFFAOYSA-N tipiracil hydrochloride Chemical compound Cl.N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 KGHYQYACJRXCAT-UHFFFAOYSA-N 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 229920002261 Corn starch Polymers 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- 235000021355 Stearic acid Nutrition 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- -1 alkali metal salts Chemical class 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 229950008138 carmellose Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000008120 corn starch Substances 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 2
- 239000003921 oil Substances 0.000 claims 2
- 239000008117 stearic acid Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 239000004386 Erythritol Substances 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- 229940009714 erythritol Drugs 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 159000000000 sodium salts Chemical group 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (13)
1. Neobložena tableta koja sadrži α,α,α-trifluorotimidin i 5-kloro-6-(2-iminopirolidin-1-il)metil-2,4(1H,3H)-pirimidin dion hidroklorid kao aktivni sastojak; koja sadrži šećerni alkohol ili disaharid kao ekscipijens, jedan ili više odabranih iz grupe koja se sastoji od hidrogeniziranih ulja i stearinske kiseline kao lubrikanta, i koja je bez aditiva koji sadrži sol metala.
2. Neobložena tableta prema patentnom zahtjevu 1, gdje je sol metala odabrana od soli alkalnih metala ili soli zemnoalkalnih metala.
3. Neobložena tableta prema patentnom zahtjevu 1 ili 2, gdje je sol metala odabrana od soli natrija, soli kalija, soli kalcija, i soli magnezija.
4. Neobložena tableta prema patentnom zahtjevu 1, gdje šećerni alkohol ili disaharid sadržan kao ekscipijens je jedan ili više odabranih od laktoze, saharoze, eritritola, i manitola.
5. Neobložena tableta prema patentnom zahtjevu 4, gdje je sadržaj šećernog alkohola ili disaharida 3.6 dijelova po masi ili više bazirano na 1 dijelu po masi α,α,α-trifluorotimidina.
6. Neobložena tableta prema bilo kom od patentnih zahtjeva 1 do 5, koja dalje sadrži jedan ili više odabranih od nisko-supstituirane hidroksipropil celuloze, kukuruznog škroba, djelomično preželatiniziranog škroba, karmeloze, i krospovidona kao agens za raspadanje.
7. Neobložena tableta prema patentnom zahtjevu 6, gdje je sadržaj agensa za raspadanje od 2 do 16% po masi u ukupnoj količini kompozicije.
8. Neobložena tableta prema patentnom zahtjevu 1, gdje je sadržaj lubrikanta od 0.001 do 3% po masi u ukupnoj kompoziciji.
9. Neobložena tableta prema bilo kom od patentnih zahtjeva 1 do 8, koja sadrži α,α,α-trifluorotimidin i 5-kloro-6-(2-iminopirolidin-1-il)metil-2,4(1H,3H)-pirimidin dion hidroklorid u molarnom odnosu od 1:0.5.
10. Neobložena tableta prema bilo kom od patentnih zahtjeva 1 do 9, gdje neobložena tableta sadrži α,α,α-trifluorotimidin i 5-kloro-6-(2-iminopirolidin-1-il)metil-2,4(1H,3H)-pirimidin dion hidroklorid kao aktivne sastojke u molarnom odnosu od 1:0.5; sadrži jedan ili više odabranih od laktoze, saharoze, ili manitola kao ekscipijens; i jedan ili više odabranih od nisko-supstituirane hidroksipropil celuloze, kukuruznog škroba, djelomično preželatiniziranog škroba, i karmeloza kao agens za raspadanje.
11. Oralna farmaceutska formulacija koja sadrži neobloženu tabletu prema bilo kojem od patentnih zahtjeva 1 do 10, gdje je tableta obložena.
12. Obložena tableta prema patentnom zahtjevu 11, gdje tableta sadrži magnezij stearat na površini.
13. Metoda za stabilizaciju neobložene tablete koja sadrži α,α,α-trifluorotimidin i 5-kloro-6-(2-iminopirolidin-1-il)metil-2,4(1H,3H)-pirimidin dion hidroklorid kao aktivni sastojak; koja sadrži šećerni alkohol ili disaharid kao ekscipijens, i jedan ili više odabranih iz grupe koja se sastoji od hidrogeniziranih ulja i stearinske kiseline kao lubrikant, naznačena time da se ne dodaje aditiv koji sadrži sol metala.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012031144 | 2012-02-15 | ||
| EP13749905.9A EP2815752B1 (en) | 2012-02-15 | 2013-02-14 | Oral pharmaceutical composition |
| PCT/JP2013/053514 WO2013122135A1 (ja) | 2012-02-15 | 2013-02-14 | 経口用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201140T1 true HRP20201140T1 (hr) | 2020-10-30 |
Family
ID=48984244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201140TT HRP20201140T1 (hr) | 2012-02-15 | 2020-07-21 | Oralna farmaceutska kompozicija |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20140363512A1 (hr) |
| EP (1) | EP2815752B1 (hr) |
| JP (1) | JP5798642B2 (hr) |
| KR (1) | KR101740105B1 (hr) |
| CN (1) | CN104105490A (hr) |
| AU (1) | AU2013219296B2 (hr) |
| CA (1) | CA2863018C (hr) |
| CY (1) | CY1123372T1 (hr) |
| DK (1) | DK2815752T3 (hr) |
| ES (1) | ES2804674T3 (hr) |
| HK (1) | HK1199821A1 (hr) |
| HR (1) | HRP20201140T1 (hr) |
| HU (1) | HUE050840T2 (hr) |
| LT (1) | LT2815752T (hr) |
| MX (1) | MX365313B (hr) |
| MY (1) | MY155938A (hr) |
| PL (1) | PL2815752T3 (hr) |
| PT (1) | PT2815752T (hr) |
| RS (1) | RS60552B1 (hr) |
| RU (1) | RU2639473C2 (hr) |
| SG (1) | SG11201403875VA (hr) |
| SI (1) | SI2815752T1 (hr) |
| TW (1) | TWI526210B (hr) |
| WO (1) | WO2013122135A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI526210B (zh) | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| CN106551946B (zh) * | 2015-09-24 | 2020-02-14 | 江苏奥赛康药业有限公司 | 一种含三氟胸苷和盐酸替比嘧啶的药物组合物及制备方法 |
| CN106913580A (zh) * | 2015-12-27 | 2017-07-04 | 南京圣和药业股份有限公司 | 一种含曲氟尿苷盐酸替哌拉索的药物组合物及其应用 |
| CN106018573B (zh) * | 2016-03-16 | 2018-09-18 | 江苏悦兴药业有限公司 | 一种tas-102中盐酸替比拉西的纯度检测方法 |
| CN105963271A (zh) * | 2016-06-01 | 2016-09-28 | 国药心制药有限公司 | 一种药用辅料组合物及一种曲氟尿苷、盐酸替匹嘧啶薄膜衣片 |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| WO2019124544A1 (ja) | 2017-12-22 | 2019-06-27 | 大鵬薬品工業株式会社 | トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法 |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
| US11730753B2 (en) * | 2018-03-03 | 2023-08-22 | Natco Pharma Limited | Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride |
| CN114917201B (zh) * | 2022-06-14 | 2024-05-31 | 国药一心制药有限公司 | 一种曲氟尿苷替匹嘧啶片剂及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
| JP3088757B2 (ja) * | 1995-03-29 | 2000-09-18 | 大鵬薬品工業株式会社 | ウラシル誘導体並びにそれを含有する抗腫瘍効果増強剤及び抗腫瘍剤 |
| JPH11322604A (ja) * | 1998-05-06 | 1999-11-24 | Pola Chem Ind Inc | ジフェニルピペラジン化合物を含有する製剤 |
| JP4110347B2 (ja) | 1999-11-05 | 2008-07-02 | 大鵬薬品工業株式会社 | 抗ｈｉｖ剤 |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| JP4601934B2 (ja) * | 2003-10-06 | 2010-12-22 | ナガセ医薬品株式会社 | ユビデカレノン錠 |
| JP2005314413A (ja) * | 2004-04-02 | 2005-11-10 | Ono Pharmaceut Co Ltd | 経口投与用医薬組成物 |
| AU2006209547C1 (en) * | 2005-01-26 | 2022-04-07 | Taiho Pharmaceutical Co., Ltd. | Anticancer drug containing alpha,alpha,alpha-trifluorothymidine and thymidine phosphorylase inhibitor |
| US7799783B2 (en) * | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP2007284390A (ja) * | 2006-04-18 | 2007-11-01 | Ohara Yakuhin Kogyo Kk | 塩酸イミダプリル含有錠剤 |
| RU2435587C2 (ru) * | 2006-06-30 | 2011-12-10 | Тайхо Фармасьютикал Ко., Лтд. | Средство, потенцирующее радиационную терапию |
| RU2346684C2 (ru) * | 2007-04-04 | 2009-02-20 | Закрытое акционерное общество "Биологические исследования и системы" | Фармацевтическая композиция на основе сигетина |
| TWI526210B (zh) | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
-
2013
- 2013-02-08 TW TW102105457A patent/TWI526210B/zh active
- 2013-02-14 WO PCT/JP2013/053514 patent/WO2013122135A1/ja active Application Filing
- 2013-02-14 SG SG11201403875VA patent/SG11201403875VA/en unknown
- 2013-02-14 JP JP2013558723A patent/JP5798642B2/ja active Active
- 2013-02-14 DK DK13749905.9T patent/DK2815752T3/da active
- 2013-02-14 KR KR1020147022338A patent/KR101740105B1/ko active IP Right Grant
- 2013-02-14 ES ES13749905T patent/ES2804674T3/es active Active
- 2013-02-14 EP EP13749905.9A patent/EP2815752B1/en active Active
- 2013-02-14 CA CA2863018A patent/CA2863018C/en active Active
- 2013-02-14 CN CN201380008605.9A patent/CN104105490A/zh active Pending
- 2013-02-14 RS RS20200855A patent/RS60552B1/sr unknown
- 2013-02-14 US US14/373,449 patent/US20140363512A1/en not_active Abandoned
- 2013-02-14 MX MX2014009834A patent/MX365313B/es active IP Right Grant
- 2013-02-14 AU AU2013219296A patent/AU2013219296B2/en active Active
- 2013-02-14 PL PL13749905T patent/PL2815752T3/pl unknown
- 2013-02-14 MY MYPI2014001998A patent/MY155938A/en unknown
- 2013-02-14 HU HUE13749905A patent/HUE050840T2/hu unknown
- 2013-02-14 SI SI201331757T patent/SI2815752T1/sl unknown
- 2013-02-14 LT LTEP13749905.9T patent/LT2815752T/lt unknown
- 2013-02-14 PT PT137499059T patent/PT2815752T/pt unknown
- 2013-02-14 RU RU2014137158A patent/RU2639473C2/ru active
-
2015
- 2015-01-12 HK HK15100293.7A patent/HK1199821A1/xx unknown
-
2020
- 2020-06-01 US US16/888,905 patent/US20200289411A1/en not_active Abandoned
- 2020-07-21 HR HRP20201140TT patent/HRP20201140T1/hr unknown
- 2020-07-23 CY CY20201100680T patent/CY1123372T1/el unknown
-
2022
- 2022-04-04 US US17/712,516 patent/US20220218602A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201140T1 (hr) | Oralna farmaceutska kompozicija | |
| HRP20171518T1 (hr) | Tabletni pripravak bez prouzrokovanja kvarova kod tabletiranja | |
| HRP20191587T1 (hr) | Formulacije s trenutnim oslobađanjem za oralnu primjenu supstituiranih kinazolinona | |
| HRP20201055T1 (hr) | Farmaceutske formulacije nitazoksanida s kontroliranim oslobađanjem | |
| HRP20161231T1 (hr) | Farmaceutske formulacije koje sadrže derivate 1-(beta-d-glukopiranozil)-2-tienilmetilbenzena kao sglt inhibitore | |
| CA2611520A1 (en) | Method and composition for pharmaceutical product | |
| HRP20141185T1 (hr) | Farmaceutski pripravci koji sadrže levetiracetam i proces za njihovu pripremu | |
| JP2010047612A5 (hr) | ||
| HRP20161262T1 (hr) | Tablete ulipristal acetata | |
| SI2023958T1 (en) | A pharmaceutical product for intravenous administration of nicotine, comprising trometamol as a buffer agent | |
| RU2009137794A (ru) | Распадающаяся во рту таблетка | |
| RU2014137096A (ru) | Перорально вводимая фармацевтическая композиция | |
| MX2011005633A (es) | Formas de dosificacion solida de bendamustina. | |
| RU2017134002A (ru) | Стабильные композиции тетрагидробиоптерина | |
| JP2007197357A5 (hr) | ||
| SI3106148T1 (en) | ORODISPERSIBILITY DOSING UNIT, CONTAINING ESTETROL COMPONENT | |
| HRP20211826T1 (hr) | Čvrste farmaceutske kompozicije koje sadrže inhibitor integraze | |
| JP2012508230A (ja) | ロスバスタチンカルシウム組成物の取得方法及び得られた産物 | |
| HRP20231670T1 (hr) | Farmaceutski pripravak za oralnu primjenu koji sadrži derivat aminopirimidina ili njegovu sol | |
| HRP20211761T1 (hr) | Dvokomponentna kompozicija koja sadrži acetilsalicilnu kiselinu | |
| JP2011512394A5 (hr) | ||
| AR075037A1 (es) | Composiciones farmaceuticas de rendimiento de producto y cumplimiento del paciente superiores | |
| PE20140962A1 (es) | Una formulacion farmaceutica solida | |
| HRP20120937T1 (hr) | Farmaceutska smjesa koja sadrži gabapentin | |
| AR087371A1 (es) | Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos |